775 — CK Life Sciences Intl (Holdings) Share Price
0.000.00%
Last trade - 00:00- HK$8.07bn
- HK$13.60bn
- HK$5.52bn
- 13
- 24
- 72
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.3 | ||
| Price to Tang. Book | 87.28 | ||
| Price to Free Cashflow | 52.4 | ||
| Price to Sales | 1.46 | ||
| EV to EBITDA | 31.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.9% | ||
| Return on Equity | -3.29% | ||
| Operating Margin | 4.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 4,942.54 | 5,402.31 | 5,275.59 | 5,322.73 | 5,522.67 | n/a | n/a | 2.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -47.55 | +57.75 | -30 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CK Life Sciences Intl (Holdings) Inc is an investment holding company principally engaged in the development and sales of healthcare products. The Company is mainly engaged in human health businesses such as research and development, production, promotion and sales of health products and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others.
Directors
- Tzar Kuoi Li CHM (56)
- Hing Lam Kam PRE (74)
- Ying Choi Yu CEO (65)
- Ka Chun Lau FID (56)
- Tak Chuen Ip SVP (68)
- Kean Meng Toh CSO (52)
- Yiu Leung Mo VFN (55)
- Kee Hung Chu VPR
- King Sang Hon GCN (60)
- Lucas Chen OTH (54)
- Wai Man Ho OTH (49)
- Mai Kuen Lee OTH (55)
- Jian-er Lin OTH (59)
- Wai Che Tong Barnes OTH (60)
- Kit Ying Wong OTH (44)
- Wai Yin Yan OTH (45)
- Eirene Yeung SEC (60)
- Peter Peace Tulloch NED (71)
- Kai Cheong Kwan NID (71)
- Eva Kwok NID (78)
- Donald Roberts NID (69)
- Colin Russel NID (80)
- Paul Tighe NID (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 1970
- Public Since
- July 16th, 2002
- No. of Employees
- 2,033
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 9,611,072,400
- Address
- 2 Dai Fu Street
- Web
- https://www.ck-lifesciences.com/
- Phone
- +852 null21261212
- Auditors
- Deloitte Touche Tohmatsu CPA
Upcoming Events for 775
Similar to 775
Asian Citrus Holdings
Stock Exchange of Hong Kong Limited
Ausnutria Dairy
Stock Exchange of Hong Kong Limited
AustAsia
Stock Exchange of Hong Kong Limited
Besunyen Holdings Co
Stock Exchange of Hong Kong Limited
Chaoda Modern Agriculture (Holdings)
Stock Exchange of Hong Kong Limited
FAQ
What is the CK Life Sciences Intl (Holdings) share price?
As of Today at 19:58 UTC, shares in CK Life Sciences Intl (Holdings) are trading at HK$0.84. This share price information is delayed by 15 minutes.
How has the CK Life Sciences Intl (Holdings) share price performed this year?
Shares in CK Life Sciences Intl (Holdings) last closed at HK$0.84 and the price had moved by +147.06% over the past 365 days. In terms of relative price strength the CK Life Sciences Intl (Holdings) share price has outperformed the FTSE Developed Asia Pacific Index by +149.88% over the past year.
What are the analyst and broker recommendations for CK Life Sciences Intl (Holdings)?
There is no consensus recommendation for this security.
Find out moreWhat is the CK Life Sciences Intl (Holdings) dividend yield?
CK Life Sciences Intl (Holdings) does not currently pay a dividend.
Does CK Life Sciences Intl (Holdings) pay a dividend?
CK Life Sciences Intl (Holdings) does not currently pay a dividend.
When does CK Life Sciences Intl (Holdings) next pay dividends?
CK Life Sciences Intl (Holdings) does not currently pay a dividend.
How do I buy CK Life Sciences Intl (Holdings) shares?
To buy shares in CK Life Sciences Intl (Holdings) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CK Life Sciences Intl (Holdings)?
As of the previous close price of HK$0.84, shares in CK Life Sciences Intl (Holdings) had a market capitalisation of HK$8.07bn.
Where are CK Life Sciences Intl (Holdings) shares listed?
Here are the trading details for CK Life Sciences Intl (Holdings):
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 775
What kind of share is CK Life Sciences Intl (Holdings)?
Based on an overall assessment of its quality, value and momentum CK Life Sciences Intl (Holdings) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CK Life Sciences Intl (Holdings) share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the CK Life Sciences Intl (Holdings) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CK Life Sciences Intl (Holdings). Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +93.5%.
As of the last closing price of HK$0.84, shares in CK Life Sciences Intl (Holdings) were trading +86.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CK Life Sciences Intl (Holdings) PE Ratio?
The CK Life Sciences Intl (Holdings) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CK Life Sciences Intl (Holdings)?
CK Life Sciences Intl (Holdings)'s management team is headed by:
- Tzar Kuoi Li - CHM
- Hing Lam Kam - PRE
- Ying Choi Yu - CEO
- Ka Chun Lau - FID
- Tak Chuen Ip - SVP
- Kean Meng Toh - CSO
- Yiu Leung Mo - VFN
- Kee Hung Chu - VPR
- King Sang Hon - GCN
- Lucas Chen - OTH
- Wai Man Ho - OTH
- Mai Kuen Lee - OTH
- Jian-er Lin - OTH
- Wai Che Tong Barnes - OTH
- Kit Ying Wong - OTH
- Wai Yin Yan - OTH
- Eirene Yeung - SEC
- Peter Peace Tulloch - NED
- Kai Cheong Kwan - NID
- Eva Kwok - NID
- Donald Roberts - NID
- Colin Russel - NID
- Paul Tighe - NID